Prevent Chronic Breast Cancer-Related Lymphedema with Early Detection and Intervention.
91% of patients believe cancer care teams should offer patients a Lymphedema Prevention Program.
Understanding fluid shifts that occur in the body can help in the early detection, management, and monitoring of chronic diseases. Lymphedema, most frequently caused by cancer or cancer treatments such as surgery, radiation, and chemotherapy, is one of the most feared consequences of cancer treatment among breast cancer survivors. If left untreated, it can become a lifelong condition.
Obtaining a baseline L-Dex® score upon breast cancer diagnosis is important for detecting breast cancer related-lymphedema and enhancing survivorship.
Utilizing the SOZO® Digital Health Platform in your clinical practice can greatly improve the quality of life for breast cancer patients and survivors1.
Dr. Pat Whitworth and Dr. Laura Lawson from the Nashville Breast Center explain why lymphedema prevention is a key component of a cancer survivorship program, and share their experience how implementing a lymphedema protocol, utilizing SOZO with L-Dex, has greatly improved the treatment and outlook for their patients.
ImpediMed’s Lymphedema Prevention Program (LPP) uses SOZO with L-Dex to help detect lymphedema in breast cancer patients at the early stage, so that it can be treated and stopped from progressing to a lifelong condition.
The L-Dex score, only available from ImpediMed, is designed to detect lymphedema-related fluid changes in the limbs.
The L-Dex score, only available from ImpediMed, is designed to detect lymphedema-related fluid changes in the limbs.
With the SOZO Digital Health Platform and L-Dex, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphedema.
NCCN Guidelines® recommend patient education and regular monitoring for the early detection of lymphedema.
Final 3-Year Primary Endpoint Results Published
The NCCN Guidelines® are consistent about the importance of early detection of lymphedema and use of an objective tool, such as bioimpedance spectroscopy.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed March 29, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Additional guidelines support early detection and intervention
